DMS 114

DMS 114 (Small Cell Lung Cancer CDX Model) 

The DMS 114 small cell lung cancer line was derived from a patient with SCLC. It is characterized by neuroendocrine features typical of this aggressive cancer subtype. The model provides a reproducible platform for drug testing in small cell lung cancer. Its consistent growth makes it useful for translational research in oncology. 

Key Features: 

• Derived from human small cell lung carcinoma. 

• Neuroendocrine morphology. 

• Highly tumorigenic in xenografts. 

• Represents aggressive SCLC biology. 

Applications: 
DMS 114 is applied in drug discovery programs for SCLC. It supports evaluation of cytotoxic and targeted therapies in this disease setting. Researchers use it to study neuroendocrine tumor mechanisms and biomarkers. Its robust growth provides reproducibility for preclinical pipelines.